Anavex Life Sciences Corp (AVXL)

[falconer66a]

Ok, Just Why No External Enthusiasm

I'm curious how you see the lack of independent reports of Anavex's potential. Most other 'up and coming' biotech's are like sugar to ants with article writers, where are they? If Anavex truely had all this great potential, the world would know it...you cannot hide this, this day in age.

Good question. If the Anavex story is so big, promising a great future for all parties: the company, its shareholders, and those many millions afflicted with central nervous system diseases; why, then, is there so little attention being given it? Except for a few of us posting here on this Ihub board, there just isn’t any visible excitement about Anavex in any related community. The investment advisory community, with but a few exceptions, has no Anavex excitement. The general press, newspapers, magazines, etc., have posted few positive, supporting, or forward-looking articles on the Anavex molecules. The investment press, Wall Street Journal, et al., are equally reticent on the subject.

For equity investors who base their buy and sell decisions on the pronouncements of each or any of those listed above, Anavex Life Sciences Corp is surely not an investment to be considered.

But, does the absence of endorsements from the listed entities necessarily disqualify Anavex as a (in time) profitable equity position? Simply, how could Anavex be a positive with such a paucity of conventional endorsements? Several reasons.

First, the Anavex technology for the treatment of central nervous system diseases is utterly new, and many would add, untested. There are no existing, approved drugs that have cellular mechanisms of actions, internal cellular workings, that the Anavex molecules have. Nothing else like them in all of medicine. Presently, for so many, an utter unknown.

Secondly, just how the Anavex sigma-1 receptor agonists provide improved health is a detailed story, difficult to understand without a pretty good understanding of cellular chemistry and physiology and structure. Offhand, just ask any of the writers of investment articles to contrast the structures and functions of both forms of endoplasmic reticula with mitochondria and have them explain how these organelles maintain homeostasis in the neuron. Then, ask them about the roles of sigma-1 receptors and their agonists.

In short, a useful understanding of the exact mechanisms of action of the Anavex molecules requires a good deal of biological knowledge. As a biologist, I note that these writers so often don’t even know the proper singulars and plurals of the involved organelles: one mitochondrion, many mitochondria; one endoplasmic reticulum, many endoplasmic reticula.

So, simply, the chemistry and physiology of the Anavex molecules is beyond comprehension for many.

But the real reason there is such a lack of external Anavex enthusiasm is that the present levels of proofs of safety and efficacy are regarded as utterly insufficient. Not enough firm, positive data upon which to base an investment decision.

And, Anavex Life Sciences Corp is a young, no-sales, no-approved-drugs pharmaceutical start-up. The success record of such companies is abysmal.

Moreover, Anavex is aiming to successfully treat impossible diseases like Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis, and a number of others; none of which can be presently treated with any degree of success. Many billions of dollars have been spent by “real” drug companies on these diseases, and each has failed. What, then, might be the chances of this unknown start-up?

Frankly, I’m not surprised at all at the lack of enthusiasm for Anavex. As the many Anavex critics will tell, it makes just good sense. For them, and so many, nothing, yet, to get excited about. Lots of negatives and question marks. Very few solid positives.

I expect all of this to continue for some time; until positive clinical trials results appear from any of the upcoming three Anavex 2-73 clinical trials. Should some little girls with Rett Syndrome miraculously improve, should some Parkinson’s patients on Anavex 2-73 improve, or, later, when the big Phase 3 Alzheimer’s trial completes and dementia symptoms are suppressed or reversed, all of what I’ve mentioned will evaporate. Suddenly, the promises of the Anavex story will have appeared and been validated. The only remaining questions will be just how soon family members and care-givers can get Anavex 2-73 for the thousands of little Susies with Rett, for the million’s of Uncle Bill’s with Parkinson’s, and the many millions of Aunt Millie’s with Alzheimer’s.